A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Dec 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ombitasvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Paritaprevir (Primary) ; Ritonavir (Primary) ; Ribavirin
Indications Hepatitis C
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms PEARL-I
Sponsors AbbVie

24 Nov 2015 According to an AbbVie media release, ombitasvir/paritaprevir/ritonavir [Technivie] tablets in combination with ribavirin have received an approval from Health Canada for the treatment of adults with genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis who are either treatment naive or previously treated with peginterferon and ribavirin.
17 Aug 2015 Results published in the Antimicrobial Agents and Chemotherapy.
24 Jul 2015 Results published in the Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com